Jazz Pharmaceuticals, Inc.

JAZZNASDAQ • USD
241.55 USD
↗ 1.18 (0.49%)AT CLOSE (03:59 PM EST)
241.51
↘ 0.04 (0.02%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
241.51
↘ 0.04 (0.02%)
🔴Market: CLOSED

JAZZ is currently priced at $241.55. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, JAZZ trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$241.77
High?$243.25
Low?$235.89
Prev. Close?$240.37
Volume?496.7K
Avg. Volume?831.0K
VWAP?$240.49
Rel. Volume?0.60x
Bid / Ask
Bid?$187.00 × 100
Ask?$259.00 × 100
Spread?$72.00
Midpoint?$223.00
Valuation & Ratios
Market Cap?15.5B
Shares Out?64.2M
Float?62.2M
Float %?95.8%
P/E Ratio?75.28
P/B Ratio?3.70
EPS?$3.21
Dividend?0.00%
Ex-Dividend?N/A
RelatedAXSM
News
Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees
2.9K
Market Cap
15.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2007-06-01
Address
FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
33
Momentum?
33
Short Sent.?
54
Piotroski F-Score?4/9Mixed
Altman Z-Score?1.93Grey
Confidence?81%High
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.33%Elevated
Short Interest?5.8M
Days to Cover?7.7
Free Float62.2M
Avg Daily Volume755.7K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.82Adequate
Quick Ratio?1.64Adequate
Cash Ratio?0.80Adequate
Debt/Equity?1.33Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
72/100
P/E?
S&P
6
75.3PRICEY▾
P/B?
Peers
100
S&P
47
3.70FAIR▾
P/S?
Peers
100
S&P
47
3.29FAIR▾
P/FCF?
S&P
88
10.0CHEAP▾
EV/EBITDA?
S&P
80
10.3CHEAP▾
EV/Sales?
Peers
100
S&P
46
4.04FAIR▾
Returns & Efficiency
ROE?
S&P
19
4.9%WEAK▾
ROA?
S&P
17
1.7%WEAK▾
Cash Flow & Enterprise
FCF?$1.5B
Enterprise Value?$19.0B
Fundamentals ratios updated end of day